½ÃÀ庸°í¼­
»óǰÄÚµå
1525328

¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð Á¶»ç : Åõ¿© °æ·Îº°, Ä¡·á¹ýº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Lyme Disease Treatment Market Size study, by Administration Route (Oral, Injectable, Topical), by Treatment (Medication, Tick Removal), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online) and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 285 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¶óÀÓº´ Ä¡·á ½ÃÀåÀº 2023³â ¾à 8¾ï 6,533¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 8.32% ÀÌ»óÀÇ °ß½ÇÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶óÀÓº´Àº °¨¿°µÈ ÂüÁøµå±â¿¡ ¹°·Á °¨¿°µÇ´Â Áúº´À¸·Î, Àü ¼¼°èÀûÀ¸·Î ¹ßº´·üÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯º´·ü Áõ°¡´Â È¿°úÀûÀÎ ¶óÀÓº´ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°¸ç ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÷´Ü Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ Á¶»ç ³ë·ÂÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Áø´Ü µµ±¸ÀÇ °³¼±°ú ÀÇ·áÁøÀÇ ÀÎ½Ä °³¼±Àº Á¶±â ¹ß°ß ¹× Á¶±â Ä¡·á·Î À̾îÁ® ÇÕº´Áõ°ú Àå±âÀûÀÎ ¿µÇâÀ» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù.

¶óÀÓº´¿¡ ´ëÇÑ ÀÎ½Ä °³¼±°ú Áø´Ü¹ýÀÌ °³¼±µÇ¸é¼­ ¶óÀÓº´ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶óÀÓº´¿¡ ´ëÇÑ ¹é½Å°ú »õ·Î¿î Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ °øµ¿ ¿¬±¸¿Í ¸·´ëÇÑ ÅõÀÚµµ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Valneva SE¿Í Pfizer Inc.´Â ¶óÀÓº´ ¹é½Å °³¹ßÀ» À§ÇØ Çù·ÂÇϰí ÀÖÀ¸¸ç, ÀÓ»ó½ÃÇè¿¡¼­ Å« ÁøÀüÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ±×·¯³ª ¶óÀÓº´ÀÌ °èÀý¼º ¾Ë·¹¸£±â³ª µ¶°¨°ú °°Àº ÀϹÝÀûÀÎ Áúº´À¸·Î ¿ÀÁøµÇ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¶óÀÓº´ÀÇ Áõ»ó°ú ºóµµ¿¡ ´ëÇÑ ´ëÁßÀÇ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå È®´ë¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Á¦¾àȸ»ç¿Í ÀÇ·á±â°üÀÇ Áö¼ÓÀûÀÎ ÀÎ½Ä °³¼± ¹× Áø´Ü °­È­ ³ë·ÂÀº ÀÌ·¯ÇÑ ¹®Á¦¸¦ ¿ÏÈ­ÇÏ°í ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À̸ç, 2023³â ÇöÀç ºÏ¹Ì°¡ ¼¼°è ½ÃÀåÀ» Áö¹èÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ °è¼Ó Áö¹èÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº ¿¬±¸ °³¹ß, ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ¶óÀÓº´¿¡ ´ëÇÑ ÀÇ·áÁø°ú ÀÏ¹Ý ´ëÁßÀÇ ³ôÀº ÀÎ½Ä ¼öÁØ¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì´Â °­·ÂÇÑ Áø´Ü ´É·Â°ú Ç×»ýÁ¦ ¹× ÁöÁö ¿ä¹ýÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀ» º¸À¯Çϰí ÀÖ´Â °Íµµ ÀåÁ¡ÀÔ´Ï´Ù. Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í ¹Î°£ ±â¾÷ÀÇ ÅõÀÚ´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ß°ú Á¾ÇÕÀûÀÎ Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ÁßÁ¡À» µÐ ºÏ¹Ì´Â ¶óÀÓº´ °ü¸®ÀÇ ¼¼°è Ç¥ÁØÀ» Çü¼ºÇϰí ÀÖÀ¸¸ç, ÀÌ Áß¿äÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ ¸®´õ½ÊÀ» È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. À¯·´ ¿ª½Ã ÀÎ½Ä °³¼±°ú ÀÇ·á¿¡ ´ëÇÑ ³ë·ÂÀ¸·Î Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ½Ã¼³ÀÇ °³¼±°ú ÀÎ½Ä Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå : ÁÖ¿ä ¿ä¾à

  • ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • Åõ¿© °æ·Îº°
    • Ä¡·áº°
    • À¯Åë ä³Îº°
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦2Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ »çÇ×
    • °ø±ÞÃø ºÐ¼®
      • °¡¿ë¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼ú Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó³âµµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
  • ½ÃÀå ±âȸ

Á¦4Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå : »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È

Á¦5Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Åõ¿© °æ·Îº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • °æ±¸
    • ÁÖ»ç
    • ±¹¼Ò

Á¦6Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Ä¡·áº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå : Ä¡·áº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • ¾à¹° ¿ä¹ý
    • Áøµå±â ±¸Á¦

Á¦7Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Åë ä³Îº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå : À¯Åë ä³Îº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ

Á¦8Àå ¼¼°èÀÇ ¶óÀÓº´ Ä¡·á ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • GSK plc.
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
      • Á¦Ç° °³¿ä
      • ½ÃÀå Àü·«
    • Pfizer, Inc.
    • Novartis AG
    • Mayne Pharma Group Limited
    • Sun Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Orion Corporation
    • Perrigo Company plc.
    • Chartwell Pharma
    • Almirall, LLC

Á¦10Àå Á¶»ç °úÁ¤

LSH 24.08.23

Global Lyme Disease Treatment Market is valued approximately at USD 865.33 million in 2023 and is anticipated to grow with a healthy growth rate of more than 8.32% over the forecast period 2024-2032. Lyme disease, a condition transmitted to humans through the bite of infected black-legged ticks, is witnessing a significant rise in incidence globally. This increasing prevalence has spurred the demand for effective Lyme disease treatments, thereby propelling market growth. Additionally, extensive research efforts to develop advanced therapies are expected to further fuel market expansion. Furthermore, improved diagnostic tools and greater awareness among healthcare providers are leading to earlier detection and treatment, reducing complications and long-term effects.

The growing incidence of Lyme disease, coupled with rising awareness and improved diagnosis, has led to a surge in demand for effective treatments. The market is also driven by collaborations and significant investments in research to develop vaccines and novel therapies for Lyme disease. For instance, Valneva SE and Pfizer Inc. have partnered to develop a Lyme disease vaccine, with significant progress in clinical trials. Such initiatives are expected to bolster the market growth. However, misdiagnosis of Lyme disease as common ailments like seasonal allergies or flu poses a challenge to market growth. Moreover, the lack of public awareness about Lyme disease symptoms and the disease's frequency can impede market expansion. Nonetheless, continuous efforts by pharmaceutical companies and healthcare organizations to enhance awareness and diagnosis are likely to mitigate these challenges and support market growth.

The key regions considered for the global Lyme disease treatment market study include Asia Pacific, North America, Europe, Latin America, and Middle East and Africa. In 2023, North America dominates the global market and is expected to continue its dominance during the forecast period. The region leads in research and development efforts, advanced healthcare infrastructure, and high awareness levels among healthcare professionals and the public about Lyme disease. Additionally, North America benefits from robust diagnostic capabilities and widespread availability of treatment options, including antibiotics and supportive therapies. Government initiatives and private sector investments further bolster market growth. With a focus on early detection and comprehensive treatment protocols, North America continues to shape global standards for managing Lyme disease, solidifying its leadership in this critical healthcare segment. Europe also holds a significant share, driven by increasing awareness and healthcare initiatives. Furthermore, the Asia Pacific region is projected to exhibit the highest growth rate, attributed to improving healthcare facilities and rising awareness.

Major market players included in this report are:

  • GSK plc.
  • Pfizer, Inc.
  • Novartis AG
  • Mayne Pharma Group Limited
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Orion Corporation
  • Perrigo Company plc.
  • Chartwell Pharma
  • Almirall, LLC

The detailed segments and sub-segment of the market are explained below:

By Administration Route

  • Oral
  • Injectable
  • Topical

By Treatment

  • Medication
  • Tick Removal

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Lyme Disease Treatment Market Executive Summary

  • 1.1. Global Lyme Disease Treatment Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Administration Route
    • 1.3.2. By Treatment
    • 1.3.3. By Distribution Channel
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Lyme Disease Treatment Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Lyme Disease Treatment Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising Incidence of Lyme Disease
    • 3.1.2. Increasing Research Initiatives
    • 3.1.3. Advancements in Diagnosis and Treatment
  • 3.2. Market Challenges
    • 3.2.1. Misdiagnosis and Lack of Awareness
    • 3.2.2. High Cost of Treatment
  • 3.3. Market Opportunities
    • 3.3.1. Collaboration and Investment in Vaccine Development
    • 3.3.2. Technological Advancements in Healthcare

Chapter 4. Global Lyme Disease Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Lyme Disease Treatment Market Size & Forecasts by Administration Route 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Lyme Disease Treatment Market: Administration Route Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 5.2.1. Oral
    • 5.2.2. Injectable
    • 5.2.3. Topical

Chapter 6. Global Lyme Disease Treatment Market Size & Forecasts by Treatment 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Lyme Disease Treatment Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 6.2.1. Medication
    • 6.2.2. Tick Removal

Chapter 7. Global Lyme Disease Treatment Market Size & Forecasts by Distribution Channel 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Lyme Disease Treatment Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies
    • 7.2.3. Online

Chapter 8. Global Lyme Disease Treatment Market Size & Forecasts by Region 2022-2032

  • 8.1. North America Lyme Disease Treatment Market
    • 8.1.1. U.S. Lyme Disease Treatment Market
      • 8.1.1.1. Administration Route breakdown size & forecasts, 2022-2032
      • 8.1.1.2. Treatment breakdown size & forecasts, 2022-2032
      • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
    • 8.1.2. Canada Lyme Disease Treatment Market
      • 8.1.2.1. Administration Route breakdown size & forecasts, 2022-2032
      • 8.1.2.2. Treatment breakdown size & forecasts, 2022-2032
      • 8.1.2.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.2. Europe Lyme Disease Treatment Market
    • 8.2.1. U.K. Lyme Disease Treatment Market
    • 8.2.2. Germany Lyme Disease Treatment Market
    • 8.2.3. France Lyme Disease Treatment Market
    • 8.2.4. Spain Lyme Disease Treatment Market
    • 8.2.5. Italy Lyme Disease Treatment Market
    • 8.2.6. Rest of Europe Lyme Disease Treatment Market
  • 8.3. Asia-Pacific Lyme Disease Treatment Market
    • 8.3.1. China Lyme Disease Treatment Market
    • 8.3.2. India Lyme Disease Treatment Market
    • 8.3.3. Japan Lyme Disease Treatment Market
    • 8.3.4. Australia Lyme Disease Treatment Market
    • 8.3.5. South Korea Lyme Disease Treatment Market
    • 8.3.6. Rest of Asia-Pacific Lyme Disease Treatment Market
  • 8.4. Latin America Lyme Disease Treatment Market
    • 8.4.1. Brazil Lyme Disease Treatment Market
    • 8.4.2. Mexico Lyme Disease Treatment Market
    • 8.4.3. Rest of Latin America Lyme Disease Treatment Market
  • 8.5. Middle East & Africa Lyme Disease Treatment Market
    • 8.5.1. Saudi Arabia Lyme Disease Treatment Market
    • 8.5.2. South Africa Lyme Disease Treatment Market
    • 8.5.3. Rest of Middle East & Africa Lyme Disease Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. GSK plc.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Market Strategies
    • 9.3.2. Pfizer, Inc.
    • 9.3.3. Novartis AG
    • 9.3.4. Mayne Pharma Group Limited
    • 9.3.5. Sun Pharmaceutical Industries Ltd.
    • 9.3.6. Lupin Pharmaceuticals, Inc.
    • 9.3.7. Orion Corporation
    • 9.3.8. Perrigo Company plc.
    • 9.3.9. Chartwell Pharma
    • 9.3.10. Almirall, LLC

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦